Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Writing a Correct Hardware ISR A hardware ISR fires at any point in your programs execution between any two instructions, with the program in an unknown register state
Choosing the Right Solvent for Your Peptide The right solvent depends on the peptides chemistry
Public health should never be guided by ideology over evidence
November 25 Product: Shorla Oncologys Imkeldi Indication: Several forms of leukemia and other cancers The FDA on Monday signed off on Shorla Oncologys Imkeldi, an oral solution indicated for the treatment of certain types of chronic myeloid leukemia and acute lymphoblastic leukemia, as well as other cancers such as myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis and dermatofibrosarcoma protuberans
